From December 3rd to 5th, 2025, the RAFA Topaz Utama team conducted a strategic visit to Luoyang and Guangzhou, China, to directly assess the latest technological advancements of our principal partners. At the Huayuekeju facility, we were introduced to a promising breakthrough in anatomical pathology laboratory efficiency: the first fully automated Liquid Based Cytology (LBC) system. Witnessing firsthand how this instrument processes samples from start to finish without manual intervention gave us renewed optimism regarding how laboratories in Indonesia can significantly reduce turnaround times without compromising diagnostic accuracy.

Our discussions continued with Geneture, where the focus shifted to molecular biology advancements through a showcase of the Amy series extraction instruments (16L, 32, and 16S) as well as their Next Generation Sequencing (NGS) solutions. One of the most compelling points of discussion was the high adoption rate of Non-Invasive Prenatal Testing (NIPT) in China, where nearly half of expectant mothers now opt for this screening to ensure fetal health—a trend highly relevant for adaptation in our market. Furthermore, assisted reproductive technology is becoming increasingly precise; the offered IVF solutions now enable detailed assessment of embryo viability prior to implantation, providing higher hopes of success for couples seeking to conceive.

In the realm of oncology and advanced genetics, Geneture demonstrated the impressive capabilities of their Tumor Panel, which can scan up to 1,100 genes for comprehensive cancer detection. We also explored the potential of Whole Exome Sequencing (WES), which has broad applications for various genetic disorders. The best news for our partners in Indonesia is Geneture’s readiness to provide full support in the form of customized bioinformatics solutions tailored to specific target genes. This initiative is not merely about acquiring instruments; it is about building a diagnostic ecosystem that is both intelligent and solution-oriented.